Enhancing the immune stimulatory effects of cetuximab therapy through TLR3 signalling in Epstein-Barr virus (EBV) positive nasopharyngeal carcinoma

References

• Ma BB, Chan AT. Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma. Cancer. 2005;103:22–31. doi:10.1002/cncr.20768.
   PubMed Web of Science ®Google Scholar
• Meng R, Wei K, Xia L, Xu Y, Chen W, Zheng R, Lin L. Cancer incidence and mortality in Guangdong province, 2012. Chin J Cancer Res. 2016;28:311–320. doi:10.21147/j.issn.1000-9604.2016.03.05.
   PubMed Web of Science ®Google Scholar
• Chee J, Ting Y, Ong YK, Chao SS, Loh KS, Lim CM. Relapse status as a prognostic factor in patients receiving salvage surgery for recurrent or residual nasopharyngeal cancer after definitive treatment. Head & Neck. 2016;38:1393–1400. doi:10.1002/hed.v38.9.
   PubMed Web of Science ®Google Scholar
• Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, Bosch W, Morrison WH, Quivey J, Thorstad W, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol. 2009;27:3684–3690. doi:10.1200/JCO.2008.19.9109.
   PubMed Web of Science ®Google Scholar
• Tham IW, Hee SW, Yeo RM, Salleh PB, Lee J, Tan TW, Fong KW, Chua ET, Wee JT-S. Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy-the national cancer centre singapore experience. Int J Radiat Oncol Biol Phys. 2009;75:1481–1486. doi:10.1016/j.ijrobp.2009.01.018.
   PubMed Web of Science ®Google Scholar
• Mak HW, Lee SH, Chee J, Tham I, Goh BC, Chao SS, Ong YK, Loh KS, Lim CM, Gao C-Q. Clinical outcome among nasopharyngeal cancer patients in a multi-ethnic society in Singapore. PLoS ONE. 2015;10:e0126108. doi:10.1371/journal.pone.0126108.
   PubMedGoogle Scholar
• Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, Chan ATC, Huang P-Y, Benhamou E, Zhu G, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015;16:645–655. doi:10.1016/S1470-2045(15)70126-9.
   PubMed Web of Science ®Google Scholar
• Leong YH, Soon YY, Lee KM, Wong LC, Tham IWK, Ho FCH. Long-term outcomes after reirradiation in nasopharyngeal carcinoma with intensity-modulated radiotherapy: A meta-analysis. Head & Neck. 2018;40:622–631. doi:10.1002/hed.24993.
   PubMed Web of Science ®Google Scholar
• Au KH, Ngan RKC, Ng AWY, Poon DMC, Ng WT, Yuen KT, Lee VHF, Tung SY, Chan ATC, Sze HCK, et al. Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study). Oral Oncol. 2018;77:16–21. doi:10.1016/j.oraloncology.2017.12.004.
   PubMed Web of Science ®Google Scholar
• Chan AT, Hsu MM, Goh BC, Hui EP, Liu TW, Millward MJ, Hong R-L, Whang-Peng J, Ma BBY, To KF, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol. 2005;23:3568–3576. doi:10.1200/JCO.2005.02.147.
   PubMed Web of Science ®Google Scholar
• Lee SC, Srivastava RM, Lopez-Albaitero A, Ferrone S, Ferris RL. Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res. 2011;50:248–254. doi:10.1007/s12026-011-8231-0.
   PubMed Web of Science ®Google Scholar
• Ming Lim C, Stephenson R, Salazar AM, Ferris RL. TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR head and neck cancer cells. Oncol Immunol. 2013;2:e24677. doi:10.4161/onci.24677.
   Google Scholar
• Gourzones C, Barjon C, Busson P. Host-tumor interactions in nasopharyngeal carcinomas. Semin Cancer Biol. 2012;22:127–136. doi:10.1016/j.semcancer.2012.01.002.
   PubMed Web of Science ®Google Scholar
• Wang N, Liang H, Zen K. Molecular mechanisms that influence the macrophage m1-m2 polarization balance. Front Immunol. 2014;5:614. doi:10.3389/fimmu.2014.00614.
   PubMed Web of Science ®Google Scholar
• Enninga EAL, Chatzopoulos K, Butterfield JT, Sutor SL, Leontovich AA, Nevala WK, Flotte TJ, Markovic SN. CD206-positive myeloid cells bind galectin-9 and promote a tumor-supportive microenvironment. J Pathol. 2018. doi:10.1002/path.5093.
   PubMed Web of Science ®Google Scholar
• Iwakiri D, Zhou L, Samanta M, Matsumoto M, Ebihara T, Seya T, Imai S, Fujieda M, Kawa K, Takada K. Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J Exp Med. 2009;206:2091–2099. doi:10.1084/jem.20081761.
   PubMed Web of Science ®Google Scholar
• Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist. 2008;13:859–875. doi:10.1634/theoncologist.2008-0097.
   PubMed Web of Science ®Google Scholar
• Lombardi V, Van Overtvelt L, Horiot S, Moingeon P. Human dendritic cells stimulated via TLR7 and/or TLR8 induce the sequential production of Il-10, IFN-gamma, and IL-17A by naive CD4+ T cells. J Immunol. 2009;182:3372–3379. doi:10.4049/jimmunol.0801969.
   PubMed Web of Science ®Google Scholar
• Girart MV, Fuertes MB, Domaica CI, Rossi LE, Zwirner NW. Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12. J Immunol. 2007;179:3472–3479. doi:10.4049/jimmunol.179.6.3472.
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Funami K, Tanabe M, Oshiumi H, Shingai M, Seto Y, Yamamoto A, Seya T. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J Immunol. 2003;171:3154–3162. doi:10.4049/jimmunol.171.6.3154.
   PubMed Web of Science ®Google Scholar
• Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011;29:330–336. doi:10.1200/JCO.2010.30.7744.
   PubMed Web of Science ®Google Scholar
• Butowski N, Lamborn KR, Lee BL, Prados MD, Cloughesy T, DeAngelis LM, Abrey L, Fink K, Lieberman F, Mehta M, et al. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol. 2009;91:183–189. doi:10.1007/s11060-008-9705-3.
   PubMed Web of Science ®Google Scholar
• Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, Jungbluth AA, Ritter G, Aghajanian C, Bell-McGuinn K, et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res. 2012;18:6497–6508. doi:10.1158/1078-0432.CCR-12-2189.
   PubMed Web of Science ®Google Scholar
• Ammi R, De Waele J, Willemen Y, Van Brussel I, Schrijvers DM, Lion E, Smits ELJ. Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs. Pharmacol Ther. 2015;146:120–131. doi:10.1016/j.pharmthera.2014.09.010.
   PubMed Web of Science ®Google Scholar
• Li Z, Duan Y, Cheng S, Chen Y, Hu Y, Zhang L, He J, Liao Q, Yang L, Sun LQ. EBV-encoded RNA via TLR3 induces inflammation in nasopharyngeal carcinoma. Oncotarget. 2015; 6:24291–24303.
   Google Scholar
• Verillaud B, Gressette M, Morel Y, Paturel C, Herman P, Lo KW, Tsao S, Wassef M, Jimenez-Pailhes A-S, Busson P. Toll-like receptor 3 in Epstein-Barr virus-associated nasopharyngeal carcinomas: consistent expression and cytotoxic effects of its synthetic ligand poly(A:U) combined to a Smac-mimetic. Infect Agent Cancer. 2012;7:36. doi:10.1186/1750-9378-7-36.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Sun R, Liu B, Deng M, Zhang W, Li Y, Zhou G, Xie P, Li G, Hu J. TLR3 activation inhibits nasopharyngeal carcinoma metastasis via downregulation of chemokine receptor CXCR4. Cancer Biol Ther. 2009;8:1826–1830. doi:10.4161/cbt.8.19.9437.
   PubMed Web of Science ®Google Scholar
• Hasan UA, Caux C, Perrot I, Doffin AC, Menetrier-Caux C, Trinchieri G, Tommasino M, Vlach J. Cell proliferation and survival induced by Toll-like receptors is antagonized by type I IFNs. Proc Natl Acad Sci U S A. 2007;104:8047–8052. doi:10.1073/pnas.0700664104.
   PubMed Web of Science ®Google Scholar
• Bondhopadhyay B, Moirangthem A, Basu A. Innate adjuvant receptor Toll-like receptor 3 can promote breast cancer through cell surface. Tumour Biol: J Int Soc Oncodevelop Biol Med. 2015;36:1261–1271. doi:10.1007/s13277-014-2737-8.
   PubMedGoogle Scholar
• Ferris RL. Immunology and Immunotherapy of Head and Neck Cancer. J Clin Oncol. 2015;33:3293–3304. doi:10.1200/JCO.2015.61.1509.
   PubMed Web of Science ®Google Scholar
• Ghesquières H, Dogan A, Link BK, Maurer MJ, Cunningham JM, Novak AJ, Larrabee BR, Slager SL, Allmer C, Habermann TM, et al. FCGR2A and FCGR3A polymorphisms in classical Hodgkin lymphoma by Epstein–barr virus status. Leuk Lymphoma. 2013;54:2571–2573. doi:10.3109/10428194.2013.796048.
   PubMed Web of Science ®Google Scholar
• Chew V, Tow C, Huang C, Bard-Chapeau E, Copeland NG, Jenkins NA, Weber A, Lim KH, Toh HC, Heikenwalder M, et al. Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients. J Natl Cancer Inst. 2012;104:1796–1807. doi:10.1093/jnci/djs436.
   PubMedGoogle Scholar
• Sivori S, Falco M, Della Chiesa M, Carlomagno S, Vitale M, Moretta L, Moretta A. CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci U S A. 2004;101:10116–10121. doi:10.1073/pnas.0403744101.
   PubMed Web of Science ®Google Scholar
• Stephenson RM, Lim CM, Matthews M, Dietsch G, Hershberg R, Ferris RL. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells. Cancer Immunol Immunother: CII. 2013;62:1347–1357. doi:10.1007/s00262-013-1437-3.
   PubMed Web of Science ®Google Scholar
• Zhou J, Dudley ME, Rosenberg SA, Robbins PF. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J Immunother. 2005;28:53–62.
   PubMed Web of Science ®Google Scholar
• Wang BG, Yi DH, Liu YF. TLR3 gene polymorphisms in cancer: a systematic review and meta-analysis. Chin J Cancer. 2015;34:19. doi:10.1186/s40880-015-0020-z.
   PubMed Web of Science ®Google Scholar
• Cheng D, Hao Y, Zhou W, Ma Y. Association between Toll-like receptor 3 polymorphisms and cancer risk: a meta-analysis. Tumour Biol: J Int Soc Oncodevelop Biol Med. 2014;35:7837–7846. doi:10.1007/s13277-014-2049-z.
   PubMedGoogle Scholar
• Moumad K, Lascorz J, Bevier M, Khyatti M, Ennaji MM, Benider A, Huhn S, Lu S, Chouchane L, Corbex M, et al. Genetic polymorphisms in host innate immune sensor genes and the risk of nasopharyngeal carcinoma in North Africa. G3 (Bethesda). 2013;3:971–977. doi:10.1534/g3.112.005371.
   PubMedGoogle Scholar
• Zeljic K, Supic G, Jovic N, Kozomara R, Brankovic-Magic M, Obrenovic M, Magic Z. Association of TLR2, TLR3, TLR4 and CD14 genes polymorphisms with oral cancer risk and survival. Oral Dis. 2014;20:416–424. doi:10.1111/odi.12144.
   PubMed Web of Science ®Google Scholar
• You R, Hua YJ, Liu YP, Yang Q, Zhang YN, Li JB, Li C-F, Zou X, Yu T, Cao J-Y, et al. Concurrent chemoradiotherapy with or without anti-egfr-targeted treatment for stage II-IVb nasopharyngeal carcinoma: retrospective analysis with a large cohort and long follow-up. Theranostics. 2017;7:2314–2324. doi:10.7150/thno.19710.
   PubMed Web of Science ®Google Scholar